Learn typical CJC 1295 no DAC dosing, injection timing, half-life, and how it compares with CJC-1295 DAC and ipamorelin. Not FDA-approved for human use.
CJC 1295 no DAC dosing in research settings typically falls between 100 mcg and 300 mcg per injection, given one to three times per day, with 100 mcg per dose being the most commonly cited starting point. CJC-1295 without DAC is a growth hormone-releasing hormone (GHRH) analog sold strictly for laboratory research, and it is not FDA-approved for human use. Because the peptide clears the bloodstream in about 30 minutes, most reported protocols split the daily amount into smaller, more frequent doses rather than a single injection.
What Is CJC-1295 No DAC?
CJC-1295 no DAC is the peptide also known as mod GRF(1-29) or modified GRF 1-29. It is a 29-amino-acid fragment designed to mimic natural GHRH and prompt the pituitary to release growth hormone.
The phrase no DAC refers to the absence of a drug affinity complex, a maleimide group that binds to albumin in the blood. Without that linker, the peptide is far less stable, which is why the two versions are dosed so differently.
CJC-1295 without DAC is a research chemical. It is not approved by the FDA for human use, and it is not a treatment for any medical condition.
Typical CJC 1295 No DAC Dosing Ranges
Reported protocols vary, but the amounts below appear most often in research summaries and community discussions. None of these figures are medical recommendations.
| Protocol Type | Dose Per Injection | Frequency | Notes |
|---|---|---|---|
| Standard research reference | 100 mcg | 1-3 times daily | Most frequently cited figure |
| Weight-based | 1-2 mcg per kg | 2-3 times daily | Scales the dose to body weight |
| Combined with a GHRP | 100 mcg CJC plus 100-200 mcg ipamorelin | 2-3 times daily | Most common stacking pattern |
| Lower bound | 50 mcg | 1-2 times daily | Sometimes used to limit side effects |
Many researchers compare cjc-1295 no dac dosing schedules that spread smaller amounts across the day against fewer, larger injections. The trade-off is convenience versus a smoother, more natural hormone pulse.
Injection Timing, Frequency, and Half-Life
Because cjc 1295 no dac half-life is short, roughly 30 minutes, timing matters more than it does with the DAC version. Natural growth hormone release happens in pulses, particularly during deep sleep and after intense exercise.
Timing choices that appear most often in reported protocols include:
- Before bed, to align with the largest natural GH pulse of the day
- After training, when growth hormone is already elevated
- On an empty stomach, since food and rising insulin may blunt the response
Once-daily use is simpler to follow. Two or three injections per day mirror how the body releases GHRH naturally. People who report flushing or headaches often reduce frequency first.
Any decision about injecting a research peptide belongs with a licensed healthcare professional, not a forum thread.
CJC-1295 DAC vs No DAC
The central difference is half-life, not the basic mechanism. CJC-1295 with DAC binds to albumin and stays active for days, while the version without DAC is largely gone within an hour.
| Feature | CJC-1295 With DAC | CJC-1295 Without DAC |
|---|---|---|
| Half-life | About 6-8 days | About 30 minutes |
| Injection frequency | Every few days to weekly | 1-3 times daily |
| Typical research dose | 1-2 mg per week | 100-300 mcg per day, split |
| GH pattern | Continuous elevation | Short, discrete pulses |
| FDA approval | Not approved for human use | Not approved for human use |
The cjc-1295 dac vs no dac debate usually comes down to whether a steady baseline or a pulse resembling natural physiology is preferable. Neither version is FDA-approved, and both carry unknown long-term risks.
Stacking With Ipamorelin
CJC-1295 no DAC is frequently paired with a growth hormone-releasing peptide such as ipamorelin. GHRH analogs and GHRPs act on different receptors, so the combination may produce a larger GH pulse than either alone in research models.
A commonly discussed stack uses 100 mcg of CJC-1295 no DAC plus 100-200 mcg of ipamorelin, two to three times daily. Reports about hunger, water retention, and sleep quality vary widely between individuals.
Threads like the cjc-1295 no dac ipamorelin reddit discussions mix personal anecdotes with speculation, so they read better as stories than as evidence.
Tesamorelin vs CJC-1295 No DAC
Tesamorelin is an FDA-approved GHRH analog indicated for reducing visceral fat in adults with HIV-associated lipodystrophy. CJC-1295 no DAC is not approved for any human use.
When tesamorelin vs cjc-1295 no dac comes up in conversation, the meaningful differences are regulatory status, studied clinical outcomes, and duration of action. Tesamorelin has human trial data and a defined prescription dose; CJC-1295 without DAC has neither.
Side Effects and Safety Considerations
Reported side effects of GHRH analogs include injection-site irritation, flushing, headache, dizziness, and fatigue. Water retention and joint discomfort are also commonly mentioned.
Safety concerns that deserve more attention than they usually get:
- Long-term effects of chronically raising growth hormone are not established for these compounds
- Purity and identity of research peptides sold online are often unverified
- Growth hormone excess has been linked to insulin resistance and tissue overgrowth
- Peptides can interact with other medications and existing health conditions
Anyone considering use should consult a licensed healthcare professional. Self-experimentation with unapproved peptides carries real risk, and no internet protocol replaces medical supervision.
Legal and Regulatory Status in the US
CJC-1295 no DAC is sold as a research chemical and labeled not for human consumption. It is not an FDA-approved drug, and it is not a dietary supplement.
Importing or possessing research peptides sits in a gray area that depends on state law and intended use. Buyers should understand that product quality, sterility, and actual peptide content are not guaranteed by any regulator.
Frequently Asked Questions
What is a typical CJC 1295 no DAC dose?
Most research and community protocols cite 100 mcg per injection, one to three times daily, while weight-based versions use about 1-2 mcg per kilogram of body weight. These figures come from laboratory summaries and user reports, not from approved medical guidance. CJC-1295 without DAC is not FDA-approved for human use, so any dosing question should go to a licensed clinician.
How long does CJC-1295 without DAC stay active?
Its half-life is roughly 30 minutes, which is why it is injected more often than CJC-1295 with DAC. Growth hormone levels rise shortly after injection and return toward baseline within a few hours. That short window is the main reason users split doses across the day.
Can CJC 1295 no DAC be stacked with ipamorelin?
It is commonly combined with ipamorelin in reported protocols, usually at 100 mcg of CJC-1295 no DAC plus 100-200 mcg of ipamorelin per injection. The two compounds act on different receptors, which is the rationale for stacking. However, no large human trials confirm the safety or effectiveness of that combination.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.